Veracyte, Inc.
NASDAQ:VCYTBiotechnology
+$1.83 today
- Market cap
- $2.06B
- Beta
- 1.98
- P/E (TTM)
- 48.0
- EPS (TTM)
- $1.11
Volume 2.45M
Average 1.05M
VCYT Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Veracyte, Inc.NASDAQ: VCYT
Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026
Cost of revenue grows in line with its trailing trend
Q2 FY2026 cost of revenue of $41.77M rose 3.4% year over year, in line with the +3.1% change in trailing-twelve-month cost of revenue. Sequentially, it rose 8.5% from the prior quarter. Over 3 fiscal years it compounded at +15.6% a year.
Context
- Cost of revenue amounted to 30.4% of revenue in FY2025, down 2.7 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +3.4% holds above the trailing-twelve-month pace of +3.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 157.1M USD
- Year-over-year change
- +6.4%
- 4-year CAGR
- +20.5%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 157.1M | +6.4% |
| FY2024 | 2024-12-31 | 147.62M | +30.7% |
| FY2023 | 2023-12-31 | 112.9M | +11.1% |
| FY2022 | 2022-12-31 | 101.58M | +36.5% |
| FY2021 | 2021-12-31 | 74.4M | — |
Cost of Revenue vs competitors
How VCYT compares with its peers on the latest reported figures
- VCYT's LTM Jun 2026 cost of revenue of $156.8M is the 4th highest of the 10 companies compared; the peer median is $114.19M.
- Its year-over-year change of +3.1% is the 7th highest of 10, against a peer median of +13.2%.
- Cost of revenue amounts to 27.9% of revenue for VCYT, versus a peer median of 31.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $445.18M | +36.1% | +30.7% | 34.8% | |
| LTM Jun 2026 | $437.4M | +13.2% | +11.4% | 57.1% | |
| LTM Mar 2026 | $249M | -0.1% | +7.1% | 30.0% | |
| LTM Jun 2026 | $156.8M | +3.1% | +15.6% | 27.9% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $144.53M | +21.5% | -20.9% | 31.8% |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $114.19M | +39.8% | — | 28.7% |
| LTM Mar 2026 | $77.95M | +24.3% | +30.4% | 22.9% | |
| LTM Mar 2026 | $55.67M | -2.6% | +1.4% | 86.3% | |
| LTM Mar 2026 | $17.22M | +7.0% | +5.7% | 17.9% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $1.57M | -13.9% | +58.2% | 80.5% |
| Peer median (excluding VCYT) | $114.19M | +13.2% | +9.2% | 31.8% | |
Competitors are the stored peer set for VCYT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 219.51M | 296.54M | 361.05M | 445.76M | 517.15M |
| Cost of Revenue | 74.4M | 101.58M | 112.9M | 147.62M | 157.1M |
| Gross Profit | 145.11M | 194.95M | 248.15M | 298.15M | 360.05M |
| Gross Margin | 66.1% | 65.7% | 68.7% | 66.9% | 69.6% |
| Research & Development | 29.84M | 40.6M | 57.31M | 69.29M | 70.81M |
| Selling, General & Admin | 181.19M | 174.08M | 184.23M | 206.04M | 210.95M |
| Operating Expenses | 227.02M | 236.04M | 333.94M | 282M | 285.9M |
| Depreciation & Amortization | 19.59M | 25.93M | 27.19M | 23.46M | 21.42M |
| EBITDA | (61.82M) | (10.3M) | (49.41M) | 49.21M | 89.62M |
| EBITDA Margin | -28.2% | -3.5% | -13.7% | 11.0% | 17.3% |
| Operating Income | (81.9M) | (41.08M) | (85.8M) | 16.14M | 74.15M |
| Operating Margin | -37.3% | -13.9% | -23.8% | 3.6% | 14.3% |
| Interest Income | 135K | 1.97M | 7.34M | 11.15M | 0 |
| Interest Expense | 241K | 198K | 15K | 2K | 0 |
| Other Income / Expenses | 254K | 4.65M | 9.18M | 9.6M | (5.95M) |
| Income Before Tax | (81.65M) | (36.43M) | (76.61M) | 25.74M | 68.2M |
| Pre-Tax Margin | -37.2% | -12.3% | -21.2% | 5.8% | 13.2% |
| Income Tax Expense | (6.09M) | 133K | (2.21M) | 1.61M | 1.85M |
| Net Income | (75.56M) | (36.56M) | (74.4M) | 24.14M | 66.35M |
| Net Margin | -34.4% | -12.3% | -20.6% | 5.4% | 12.8% |
| EPS (Basic) | (1.11) | (0.51) | (1.02) | 0.32 | 0.84 |
| EPS (Diluted) | (1.11) | (0.51) | (1.02) | 0.31 | 0.82 |
| Weighted Avg Shares | 67.89M | 71.55M | 72.64M | 76.48M | 78.58M |
| Weighted Avg Shares (Diluted) | 67.89M | 71.55M | 72.64M | 78.16M | 80.57M |
Veracyte, Inc.
NASDAQ:VCYT
Intrinsic Alpha fair value
Locked
Current Price
$25.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.